keyword
MENU ▼
Read by QxMD icon Read
search

Stage 4 colorectal cancer

keyword
https://www.readbyqxmd.com/read/27920498/feasibility-of-sequential-adjuvant-chemotherapy-with-a-3-month-oxaliplatin-based-regimen-followed-by-3-months-of-capecitabine-in-patients-with-stage-iii-and-high-risk-stage-ii-colorectal-cancer-jswog-c2-study
#1
Atsushi Tsuruta, Kazuki Yamashita, Hiroaki Tanioka, Akihito Tsuji, Michio Inukai, Toshiki Yamakawa, Tomoki Yamatsuji, Masanori Yoshimitsu, Kazuhiro Toyota, Taketoshi Yamano, Takeshi Nagasaka, Masazumi Okajima
BACKGROUND: Six months of oxaliplatin-based chemotherapy is the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC). Also, patients with stage II CRC who are considered to be at high risk of disease recurrence often receive the same adjuvant chemotherapy treatment. We prospectively investigated the extent and degree of neuropathy suffered by stage III and high-risk stage II resectable CRC patients who underwent sequential approach involving 3 months of an oxaliplatin-based regimen followed by 3 months of capecitabine...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27914767/smad-4-gene-expression-in-human-colorectal-cancer-comparison-with-some-clinical-and-pathological-parameters
#2
Agnieszka Wosiak, Damian Wodziński, Marcin Kolasa, Aleksandra Sałagacka-Kubiak, Ewa Balcerczak
The aim of this study was to evaluate the expression of SMAD-4 gene in cases of colorectal cancer and to link the obtained data with the development of this disease. SMAD-4 gene is responsible for the control of many important cellular processes, for example prevention of excessive epithelial cell growth and divisions. This suppressor gene is located on chromosome 18 within the region with frequent genetic losses in colorectal cancer. Inactivation of this gene is commonly found in pancreatic cancer where the SMAD-4 gene lost in the expression has been associated with a poor prognosis in this cancer...
October 26, 2016: Pathology, Research and Practice
https://www.readbyqxmd.com/read/27904859/endoscopic-approach-for-superficial-colorectal-neoplasms
#3
REVIEW
Jun-Feng Xu, Lang Yang, Peng Jin, Jian-Qiu Sheng
BACKGROUND: Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths in 2012. Colonoscopy is the cornerstone for the detection and prevention of CRC. In addition, endoscopic treatment for CRC at an early stage can effectively improve patients' quality of life and cure rate. SUMMARY: This review focuses on endoscopic approaches, including white light endoscopy, chromoendoscopy, magnifying endoscopy and therapeutic endoscopy, for the evaluation and treatment of superficial colorectal neoplasms...
October 2016: Gastrointestinal Tumors
https://www.readbyqxmd.com/read/27900008/discovery-of-genes-from-feces-correlated-with-colorectal-cancer-progression
#4
Chia-Long Lee, Chi-Jung Huang, Shung-Haur Yang, Chun-Chao Chang, Chi-Cheng Huang, Chih-Cheng Chien, Ruey-Neng Yang
Colorectal cancer (CRC) is considered to develop slowly via a progressive accumulation of genetic mutations. Markers of CRC may serve to provide the basis for decision-making, and may assist in cancer prevention, detection and prognostic prediction. DNA and messenger (m)RNA molecules that are present in human feces faithfully represent CRC manifestations. In the present study, exogenous mouse cells verified the feasibility of total fecal RNA as a marker of CRC. Furthermore, five significant genes encoding solute carrier family 15, member 4 (SLC15A4), cluster of differentiation (CD)44, 3-oxoacid CoA-transferase 1 (OXCT1), placenta-specific 8 (PLAC8) and growth arrest-specific 2 (GAS2), which are differentially expressed in the feces of CRC patients, were verified in different CRC cell lines using quantitative polymerase chain reaction...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27891772/twoplex-12-13-c6-aniline-stable-isotope-and-linkage-specific-sialic-acid-labelling-2d-lc-ms-workflow-for-quantitative-n-glycomics
#5
Simone Albrecht, Stefan Mittermayr, Josh Smith, Silvia Millán Martín, Margaret Doherty, Jonathan Bones
Quantitative glycomics represents an actively expanding research field ranging from the discovery of disease associated glycan alterations to the quantitative characterization of N-glycans on therapeutic proteins. Commonly used analytical platforms for comparative relative quantitation of complex glycan samples include MALDI-ToF-MS or chromatographic glycan profiling with subsequent data alignment and statistical evaluation. Limitations of such approaches include run-to-run technical variation and the potential introduction of subjectivity during data processing...
November 28, 2016: Proteomics
https://www.readbyqxmd.com/read/27888803/exosomal-long-noncoding-rna-crnde-h-as-a-novel-serum-based-biomarker-for-diagnosis-and-prognosis-of-colorectal-cancer
#6
Tong Liu, Xin Zhang, Shanyu Gao, Fangmiao Jing, Yongmei Yang, Lutao Du, Guixi Zheng, Peilong Li, Chen Li, Chuanxin Wang
Cancer-secreted long non-coding RNAs (lncRNAs) are emerging mediators of cancer-host cross talk. The aim of our study was to illustrate the clinical significance of the lncRNA CRNDE-h in exosomes purified from the serum of patients with colorectal cancer (CRC). The study was divided into four parts: (1) The exosome isolated methods and lncRNA detected methods which accurately and reproducibly measure CRC-related exosomal CRNDE-h in serum were optimized in preliminary pilot stage; (2) The stability of exosomal CRNDE-h was evaluated systematically; (3) The origin of exosomal CRNDE-h was explorated in vitro and in vivo; (4) The diagnostic and prognostic value of exosomal CRNDE-h for CRC were validated in 468 patients...
November 19, 2016: Oncotarget
https://www.readbyqxmd.com/read/27885879/a-high-preoperative-carbohydrate-antigen-19-9-level-is-a-risk-factor-for-recurrence-in-stage-ii-colorectal-cancer
#7
Hiroaki Nozawa, Soichiro Ishihara, Kazushige Kawai, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Kazuhito Sasaki, Koji Murono, Toshiaki Watanabe
BACKGROUND: Many risk factors for recurrence in stage II colorectal cancer (CRC) have been proposed, and the efficacy of adjuvant chemotherapy is still controversial. This study aimed to identify risk factors for tumor recurrence and assess whether they are related to the benefits of adjuvant chemotherapy in stage II CRC. MATERIAL AND METHODS: Patients with stage II CRC that was curatively operated on in a tertiary hospital between 2005 and 2014 were analyzed. Cox's proportional hazards models were applied to identify risk factors for recurrence and overall mortality...
November 25, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27876677/do-we-really-need-the-full-compliance-with-eras-protocol-in-laparoscopic-colorectal-surgery-a-prospective-cohort-study
#8
Magdalena Pisarska, Michał Pędziwiatr, Piotr Małczak, Piotr Major, Sebastian Ochenduszko, Anna Zub-Pokrowiecka, Jan Kulawik, Andrzej Budzyński
BACKGROUND: Although the relation between adherence to the ERAS protocol and clinical outcomes was extensively studied, there is still ongoing discussion on the need and feasibility of full compliance in laparoscopic colorectal surgery. In this study, we aimed to verify whether a strict adherence to the protocol (>90%) leads to further improvement in clinical outcomes compared to high (70-90%) and low (<70%) compliance groups. MATERIALS AND METHODS: The analysis included consecutive prospectively registered patients operated laparoscopically for colorectal cancer between January 2012 and December 2015...
November 19, 2016: International Journal of Surgery
https://www.readbyqxmd.com/read/27873100/the-pretreatment-systemic-inflammatory-response-is-an-important-determinant-of-poor-pathologic-response-for-patients-undergoing-neoadjuvant-therapy-for-rectal-cancer
#9
Stephan B Dreyer, Arfon G M T Powell, Stephen T McSorley, Ashita Waterston, James J Going, Joanne Edwards, Donald C McMillan, Paul G Horgan
BACKGROUND: Not all patients respond equally to neoadjuvant chemoradiotherapy (nCRT), with subsequent effects on survival. The systemic inflammatory response has been shown to predict long-term outcomes in colorectal cancer. The current study examined the association between systemic inflammation and nCRT in patients with rectal cancer. METHODS: Between 1999 and 2010, patients who underwent nCRT were identified. Serum measurements of hemoglobin, C-reactive protein, albumin, modified Glasgow prognostic score (mGPS), and differential white cell counts were obtained before and after nCRT...
November 21, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27872975/identification-of-recurrence-predictive-indicators-in-stage-i-colorectal-cancer
#10
Jun Ho Lee, Jong Lyul Lee, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
BACKGROUND: Patients with stage I colorectal cancer (CRC) rarely experience recurrences; therefore, few risk factors for recurrence are known. This study was designed to evaluate oncologic outcomes of patients with stage I CRC and to identify risk factors for recurrence after curative surgery. METHODS: A retrospective cohort of 860 patients from a single institution who underwent curative surgery for stage I CRC between July 1995 and June 2010 was enrolled. Patients who were diagnosed with hereditary, synchronous, or metachronous cancer and those who received preoperative chemoradiotherapy were excluded...
November 21, 2016: World Journal of Surgery
https://www.readbyqxmd.com/read/27872084/patient-perspectives-on-delays-in-diagnosis-and-treatment-of-cancer-a-qualitative-analysis-of-free-text-data
#11
Rachel K Parsonage, Julia Hiscock, Rebecca-Jane Law, Richard D Neal
BACKGROUND: Earlier cancer diagnosis is crucial in improving cancer survival. The International Cancer Benchmarking Partnership Module 4 (ICBP4) is a quantitative survey study that explores the reasons for delays in diagnosis and treatment of breast, colorectal, lung, and ovarian cancer. To further understand the associated diagnostic processes, it is also important to explore the patient perspectives expressed in the free-text comments. AIM: To use the free-text data provided by patients completing the ICBP4 survey to augment the understanding of patients' perspectives of their diagnostic journey...
November 21, 2016: British Journal of General Practice: the Journal of the Royal College of General Practitioners
https://www.readbyqxmd.com/read/27866337/mental-and-physical-health-correlates-among-family-caregivers-of-patients-with-newly-diagnosed-incurable-cancer-a-hierarchical-linear-regression-analysis
#12
Kelly M Shaffer, Jamie M Jacobs, Ryan D Nipp, Alaina Carr, Vicki A Jackson, Elyse R Park, William F Pirl, Areej El-Jawahri, Emily R Gallagher, Joseph A Greer, Jennifer S Temel
PURPOSE: Caregiver, relational, and patient factors have been associated with the health of family members and friends providing care to patients with early-stage cancer. Little research has examined whether findings extend to family caregivers of patients with incurable cancer, who experience unique and substantial caregiving burdens. We examined correlates of mental and physical health among caregivers of patients with newly-diagnosed incurable lung or non-colorectal gastrointestinal cancer...
November 19, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27866244/efficacy-and-safety-of-nab-paclitaxel-in-patients-with-previously-treated-metastatic-colorectal-cancer-a-phase-ii-colo-001-trial
#13
Michel Ducreux, Jaafar Bennouna, Antoine Adenis, Thierry Conroy, Astrid Lièvre, Fabienne Portales, Julie Jeanes, Li Li, Alfredo Romano
PURPOSE: This single-arm, phase II trial evaluated nab-paclitaxel monotherapy in pretreated patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC (RAS wild-type and RAS mutant cohorts) received nab-paclitaxel 125 mg/m(2) days 1, 8, and 15 (28-day cycle). The primary endpoint was investigator-assessed progression-free survival (PFS) rate at week 8; secondary endpoints included overall survival, overall response rate, and safety. Stage 1 planned enrollment was 15 patients per cohort per Simon 2-stage design...
November 19, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27865249/development-and-validation-of-the-preparedness-for-colorectal-cancer-surgery-questionnaire-pcsq-pre-24
#14
E Carlsson, M Pettersson, J Öhlén, R Sawatzky, F Smith, F Friberg
PURPOSE: The aims of the study were to develop and psychometrically evaluate a patient-reported outcome instrument for the measurement of preoperative preparedness in patients undergoing surgery for colorectal cancer. METHODS: This study was conducted in two stages: a) instrument development (item generation, construction of items and domains), empirical verification and b) instrument evaluation. A questionnaire with 28 items measuring preparedness for surgery was developed covering four domains and was tested for content validity with an expert panel and with patients...
December 2016: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/27864747/surgical-management-of-metastatic-colorectal-cancer-a-single-centre-experience-on-oncological-outcomes-of-pulmonary-resection-vs-cytoreductive-surgery-and-hipec
#15
Evelyn Yi Ting Wong, Grace Hwei Ching Tan, Deanna Wan Jie Ng, Tina Puay Theng Koh, Mrinal Kumar, Melissa Ching Ching Teo
PURPOSE: Metastasectomy is accepted as standard of care for selected patients with colorectal pulmonary metastases (CLM); however, the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases (CPM) is not universally accepted. We aim to compare oncological outcomes of patients with CLM and CPM after pulmonary resection and CRS-HIPEC, respectively, by comparing overall survival (OS) and disease-free survival (DFS). METHODS: A retrospective review of 49 CLM patients who underwent pulmonary resection, and 52 CPM patients who underwent CRS-HIPEC in a single institution from January 2003 to March 2015, was performed...
November 19, 2016: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/27863421/lncrna-gas5-contributes-to-lymphatic-metastasis-in-colorectal-cancer
#16
Yongbin Zheng, Dan Song, Kuang Xiao, Cao Yang, Yu Ding, Wenhong Deng, Shilun Tong
Colorectal cancer (CRC) ranks the third most common type of cancer worldwide. However, the detailed molecular mechanisms underlying these processes are poorly understood. Recent studies have shown that lncRNAs play important roles in carcinogenesis and progression of CRC. The lncRNA growth arrest special 5 (GAS5), was previously identified to be down-regulated and functions as a tumor suppressor gene in many kinds of cancers. In current two-stage, case-control study, we systematically evaluated the potential role of lncRNA GAS5 and its genetic variation rs145204276 in the development and metastasis process of CRC in a Chinese population...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27856366/advanced-stage-colorectal-cancer-in-persons-younger-than-50-years-not-associated-with-longer-duration-of-symptoms-or-time-to-diagnosis
#17
Frank W Chen, Vandana Sundaram, Thomas A Chew, Uri Ladabaum
BACKGROUND & AIMS: The incidence of colorectal cancer (CRC) is increasing in the United States (US) among adults under the age of 50 years. Studies of young-onset CRC have focused on outcomes and treatment patterns. We examined patient presentation, provider evaluation, and time to diagnosis, which can affect stage and prognosis. METHODS: In a retrospective study, we collected data from patients with a diagnosis of colorectal adenocarcinoma, confirmed by pathologists, seen at the Stanford Cancer Institute from January 1, 2008 through December 31, 2014...
November 14, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27854066/cancer-recurrence-following-conversion-during-laparoscopic-colorectal-resections-a-meta-analysis
#18
REVIEW
Mariano Cesare Giglio, Gaetano Luglio, Viviana Sollazzo, Filomena Liccardo, Roberto Peltrini, Michele Sacco, Giovanni Spiezio, Bruno Amato, Giovanni Domenico De Palma, Luigi Bucci
INTRODUCTION: Evidence regarding long-term oncological outcomes following conversion to open surgery (COS) during laparoscopic colorectal resection (LCR) is controversial. The aim of this study is to assess the impact on cancer recurrence of a failed laparoscopic attempt. METHODS: MEDLINE, Scopus and ISI Web of Knowledge databases were searched for articles reporting data on cancer recurrence in patients undergoing completed LCR and COS. Data were pooled by fixed or random effect modeling, according to the presence of heterogeneity...
November 16, 2016: Aging Clinical and Experimental Research
https://www.readbyqxmd.com/read/27847786/use-of-a-comprehensive-geriatric-assessment-to-predict-short-term-postoperative-outcome-in-elderly-patients-with-colorectal-cancer
#19
Yoon Hyun Lee, Heung-Kwon Oh, Duck-Woo Kim, Myong Hoon Ihn, Jee Hyun Kim, Il Tae Son, Sung Il Kang, Gwang Il Kim, Soyeon Ahn, Sung-Bum Kang
PURPOSE: This study was conducted to identify the effectiveness of a preoperative comprehensive geriatric assessment (CGA) for predicting postoperative morbidity in elderly patients who underwent surgery for colorectal cancer. METHODS: Elderly patients (≥70 years old) who underwent surgery for colorectal cancer at a tertiary hospital in Korea were identified, and their cases were analyzed using data from a prospectively collected database to establish an association between major postsurgical complications and 'high-risk' patient as defined by the CGA...
October 2016: Annals of Coloproctology
https://www.readbyqxmd.com/read/27845948/5-fluorouracil-degradation-rate-could-predict-toxicity-in-stages-ii-iii-colorectal-cancer-patients-undergoing-adjuvant-folfox
#20
Concetta E Onesti, Andrea Botticelli, Marco La Torre, Marina Borro, Giovanna Gentile, Adriana Romiti, Luana Lionetto, Antonella Petremolo, Mario Occhipinti, Michela Roberto, Rosa Falcone, Maurizio Simmaco, Paolo Marchetti, Federica Mazzuca
5-Fluorouracil is commonly used for gastrointestinal cancer treatment in an adjuvant setting; however, the toxicity can lead to a reduction, delay, or discontinuation of treatment. We retrospectively investigated the association between the 5-fluorouracil degradation rate (5-FUDR) and genetic polymorphisms of TSER, DPYD, and MHTFR with toxicity in colorectal cancer patients treated with adjuvant FOLFOX. Pretreatment 5-FUDR and MTHFR A1298T or C677T, TSER, and DPYD gene polymorphisms were characterized in stages II-III colorectal cancer patients...
November 11, 2016: Anti-cancer Drugs
keyword
keyword
110220
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"